The road is far away, and the road is within reach——CSCO Autologous Transplantation Working Group 2022 Tour (Northeast Three Provinces) was a complete success

After the opening speech, the academic session kicked off
.
The first session was presided over by Professor Zhang Bolong of Lu Daopei Hospital in Yanda, Hebei Province.

Professor Chamberlain served as the chair of the first session

Professor Wang Xiaopei of Peking University Cancer Hospital gave a detailed report entitled "Current Status and Prospect of Autologous Hematopoietic Stem Cell Transplantation".

Professor Wang Xiaopei introduced the application status of ASCT in China from many aspects, such as the gap between domestic and foreign countries, the unbalanced development of various regions in China, the rapid increase in the intention of Chinese peer experts to participate in ASCT, and the increasingly abundant drug selection.
The following thoughts on the development of ASCT were put forward: (1) how to achieve the unity and specialization of ideology and concepts, and how to control every link of ASCT; (2) how to carry out new attempts to carry out secondary transplantation and pretreatment program selection in the future; (3) Explore how new therapies such as PD-1 and CAR-T can be combined with ASCT; (4) How to cooperate
with each other within and between departments.
In addition, Professor Wang Xiaopei expressed his vision to develop resources, pool wisdom and efforts, and maintain a holistic view to promote the development of ASCT through a nationwide lecture tour.
Down-to-earth, optimize and innovate, and make choices for patients in line with national conditions; Expand into the field of central nervous system, reproductive system, and bone and cartilage tissue tumors, improve the overall efficacy of treatment, and bring lasting benefits
to patients.

Professor Wang Xiaopei gave a report

In the discussion session, Professor Zhao Donglu of Harbin Institute of Hematology and Oncology and Professor Li Xiaoyun of the Second Affiliated Hospital of Harbin Medical University Professor Wang Xiaopei had an in-depth discussion with Professor Wang Xiaopei on "how to choose mobilization options and timing for patients with poor bone marrow reserve after multiple chemotherapy", "whether Plorxaf can be tried for patients with myeloid leukemia who have complete remission", and "whether there are patients who have ASCT first, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), and how to choose pretreatment programs for such patients"
。

The second session was chaired by Professor Fan Shengjin of the First Affiliated Hospital of Harbin Medical University.

Professor Fan Shengjin served as the chair of the second session

Professor Huang Wenrong of the Fifth Medical Center of PLA General Hospital gave a lecture entitled "Autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma", from four aspects
: the status of ASCT in the treatment of multiple myeloma (MM), the choice of transplant timing, the choice of ASCT pretreatment plan, and the significance of sequential secondary ASCT treatment 。 In the era of new drugs, ASCT is still irreplaceable, which helps to improve the depth of remission of MM treatment, prolong event-free survival (EFS) and overall survival (OS); Patients who are suitable for ASCT should be transplanted sooner rather than later, and ASCT
can be performed after 4 courses of initial treatment, and the efficacy evaluation reaches partial remission (PR) or above.
Melphalan (MEL) 200 mg/m2 is an effective pretreatment for ASCT, and MEL 140 mg/^m2
may be considered in elderly or severely impaired renal patients.
Patients with high-risk/extramedullary MM who respond to a first transplant but do not achieve very good partial remission (VGPR) may benefit from
a second ASCT.

Professor Huang Wenrong gave a report

In the discussion session, Professor Tan Yehui of the First Hospital of Jilin University and Professor Bai Yuansong of the China-Japan Friendship Hospital of Jilin University Participated in the discussion, and had wonderful exchanges on topics such as "whether continuing chemotherapy until deeper remission and then ASCT after reaching PR is better long-term survival than transplant patients immediately after PR", "how to choose the dose of MEL", "whether there is a difference between intravenous and oral MEL", "if oral MEL, how to adjust the drug dose for patients with different subtypes and stages of MM", and "the choice of steady-state mobilization and chemotherapy mobilization
。

The third session was chaired by Professor Yan Jinsong of the Second Affiliated Hospital of Dalian Medical University.

Professor Yan Jinsong served as the chair of the third session

Professor Jiang Erlie, Hospital of Hematology, Chinese Academy of Medical Sciences, gave a wonderful report on why ASCT should be insisted on in adult patients with acute lymphoblastic leukemia (ALL) as the starting point entitled "Hematopoietic stem cell transplantation in the treatment of adult ALL: Current situation and prospects".

Professor Jiang Erlie pointed out that although foreign studies have reported that the recurrence rate after ASCT in high-risk ALL patients is higher than that of allo-HSCT patients, this difference is not significant
in standard-risk patients.
In addition, after stopping maintenance therapy, chemotherapy patients have a higher recurrence rate after discontinuation than ASCT, and the process takes less
time from the beginning of induction therapy to ASCT and the end of maintenance therapy.
Subsequently, Professor Jiang Erlie mentioned that when patients with minimal residual disease (MRD) were negative and ASCT were performed, there was no significant difference between disease-free survival (DFS) and the allo-HSCT group, which could be maintained to more than
60%.
Finally, Professor Jiang Erlie introduced two high-risk patients who underwent ASCT after MRD-negative, both of whom benefited from ASCT and had a good
prognosis.

Professor Jiang Erlie made a report

During the discussion, Professor Wang Jigang of the General Hospital of the Northern Theater of the Chinese People's Liberation Army and Professor Jia Zhilin of the First Affiliated Hospital of Dalian Medical University were discussed Professor Jiang Erlie actively discussed
with Professor Jiang Erlie on "how to optimize the maintenance treatment plan after ASCT for ALL patients", "how to avoid contamination of stem cell collections", "whether transplantation is still required after the use of new antibody drugs", "whether the selection of drugs in the current maintenance therapy stage can be accurate to the type or target of gene mutations" and "which part of T-ALL patients can benefit from ASCT".

The fourth session was chaired by Professor Yan Xiaojing of the First Affiliated Hospital of China Medical University.

Professor Yan Xiaojing served as the host of the fourth session

Professor Zhang Xi of Xinqiao Hospital of Army Medical University gave a wonderful explanation on the topic of "Progress and Exploration of Lymphoma Autologous Hematopoietic Stem Cell Transplantation".

Professor Zhang Xi mentioned that in the era of new drugs, ASCT is still one of the important and effective means of treating hematological tumors, because of its good safety and high cost performance, China has the need to further promote ASCT, ASCT should continue to develop
in the direction of precision and deepening in the future.
For refractory relapse and high-risk patients, there is a need to
explore new approaches to ASCT+X.
The emergence of new drugs provides new ideas for the improvement of treatment programs in the pretreatment, maintenance and other stages of ASCT, there is no perfect treatment, but there is an optimized program, ASCT can be organically combined with new drugs, CAR-T and other new therapies, and calls for more multi-center clinical studies in the future to explore new technologies and new methods to improve efficacy, "empower" ASCT, and jointly improve the treatment effect
of lymphoma.

Professor Zhang Xi gave a report

During the discussion session, Professor Wang Hongtao of Shengjing Hospital affiliated to China Medical University and Professor Jiang Libo of the Second Affiliated Hospital of Qiqihar Medical College discussed "how to arrange the order of use in the combination of CAR-T and ASCT", and "young patients with primary central nervous system diffuse large B-cell lymphoma after treatment with high-dose methotrexate and zebrutinib, MRD negative and lasting for half a year, whether ASCT is still needed" and other issues, and Professor Zhang Xi had a heated discussion
.